Second study adds to hormone therapy fears
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Women using hormone replacement therapy on a long-term basis are at greater risk of developing ovarian cancer, research showed yesterday.
Women using hormone replacement therapy on a long-term basis are at greater risk of developing ovarian cancer, research showed yesterday.
Doubts about the safety of oestrogen-only HRT came a week after scientists warned that another form of the therapy increased the risk of invasive breast cancer, heart attacks and strokes.
In last week's alert, a major American study was abandoned after the dangers of taking combined HRT, which includes oestrogen and progesterone, were found to outweigh the benefits.
Now a second study in the United States has shown that women taking oestrogen-only HRT have a 60 per cent greater risk of developing ovarian cancer than women who have never used HRT.
Women using the single hormone therapy for 20 years or more are three times more likely to develop the disease, according to research at the National Cancer Institute in Bethesda, Maryland. But the likelihood of a woman contracting ovarian cancer was still very small. Out of 44,241 women taking part in the study, a total of 329 developed the disease, and only 16 cancers occurred among those who had been using HRT for more than two decades.
Women using the combined preparation did not appear to be at increased risk of ovarian cancer, according to results published in the Journal of the American Medical Association. But Dr James Lacey, who led the study, involving post-menopausal women with an average age of 56, said more research was needed before the twin-hormone therapy was cleared of any link to ovarian cancer.
Dr Kenneth Noller, from New England Medical Centre in Boston, Massachusetts, said in an accompanying article that the results were "worrisome enough" for doctors to think twice about prescribing oestrogen-only HRT. "Oestrogen replacement therapy certainly is not the panacea it once appeared," he wrote.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments